Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $12
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and raises the price target from $11 to $12.
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and raises the price target from $11 to $12.